Treatment of Inferior Lateral Pterygoid Muscle Dystonia with Zolpidem Tartrate, Botulinum Toxin Injections, and Physical Self-Regulation Procedures: A Case Report

References

• Tan EK, Jankovic J: Botulinum toxin A in patients with oromandibular dystonia: long-term follow-up. Neurol 1999; 53(9):2102–2107.
   PubMed Web of Science ®Google Scholar
• Sforza E, Montagna P, Defazio G, Lugaresi E: Sleep and cranial dystonia. Electroencephalogr Clin Neurophysiol 1991; 79(3):166–169.
   Google Scholar
• Sharma AK, Behari M, Ahuja GK: Clinical and demographic features of Meige’s syndrome. J Assoc Physicians India 1996; 44(9):645–647.
   Google Scholar
• Nutt JG, Muenter MD, Aronson A, Kurland LT, Melton LJ III: Epidemiology of focal and generalized dystonia in Rochester, Minnesota. Mov Disord 1988; 3(3):188–194.
   PubMed Web of Science ®Google Scholar
• Berardelli A, Rothwell JC, Day BL, Marsden CD: Pathophysiology of blepharospasm and oromandibular dystonia. Brain 1985; 108(Pt 3):593–608.
   Web of Science ®Google Scholar
• Defazio G, Lamberti P, Lepore V, Livrea P, Ferrari E: Facial dystonia: clinical features, prognosis, and pharmacology in 31 patients. Ital J Neurol Sci 1989; 10(6):553–560.
   Google Scholar
• Tolosa E, Marti MJ: Blepharospasm-oromandibular dystonia syndrome (Meige’s syndrome): clinical aspects. Adv Neurol 1988; 49:73–84.
   PubMedGoogle Scholar
• Esper GJ, Charles PD, Davis TL, Robertson D: Adult-onset focal dystonias: presentation and treatment options. Tenn Med 1997; 90(1):18–20.
   Google Scholar
• Steinberger D, Topka H, Fischer D, Muller U: GCH1 mutation in a patient with adult-onset oromandibular dystonia. Neurol 1999; 52(4):877–879.
   Web of Science ®Google Scholar
• Lee LV, Kupke KG, Caballar-Gonzaga F, Hebron-Ortiz M, Muller U: The phenotype of the X-linked dystonia-parkinsonism syndrome. An assessment of 42 cases in the Philippines. Medicine (Baltimore) 1991; 70(3):179–187.
   PubMed Web of Science ®Google Scholar
• Gouider-Khouja N, Miladi N, Belal S, Hentati F: Intrafamilial phenotypic variability of Hallervorden-Spatz syndrome in a Tunisian family. Parkinsonism Relat Disord 2000; 6(3):175–179.
   Web of Science ®Google Scholar
• Jankovic J, Ford J: Blepharospasm and orofacial-cervical dystonia: clinical and pharmacological findings in 100 patients. Ann Neurol 1983; 13(4):402–411.
   PubMed Web of Science ®Google Scholar
• Ransmayr G, Kleedorfer B, Dierckx RA, Poewe W, Kemmler GW, Gerstenbrand F: Pharmacological study in Meige’s syndrome with predominant blepharospasm. Clin Neuropharmacol 1988; 11(1):68–76.
   PubMed Web of Science ®Google Scholar
• Casey DE: Pharmacology of blepharospasm-oromandibular dystonia syndrome. Neurol 1980; 30(7 Pt 1):690–695.
   PubMed Web of Science ®Google Scholar
• Sutcher HD, Underwood RB, Beatty RA, Sugar O: Orofacial dyskinesia. A dental dimension. JAMA 1971; 216(9):1459–1463.
   Web of Science ®Google Scholar
• Jankovic J, Schwartz K, Donovan DT: Botulinum toxin treatment of cranial cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. J Neurol Neurosurg Psych 1990; 53(8):633–639.
   Web of Science ®Google Scholar
• Poungvarin N, Devahastin V, Chaisevikul R, Prayoonwiwat N, Viriyavejakul A: Botulinum A toxin treatment for blepharospasm and Meige syndrome: report of 100 patients. J Med Assoc Thai 1997; 80(1):1–8.
   Google Scholar
• Behari M, Singh KK, Seshadri S, Prasad K, Ahuja GK: Botulinum toxin A in blepharospasm and hemifacial spasm. J Assoc Physicians India 1994; 42(3):205–208.
   Google Scholar
• Blitzer A, Brin MF, Greene PE, Fahn S: Botulinum toxin injection for the treatment of oromandibular dystonia. Ann Otol Rhinol Laryngol 1989; 98(2):93–97.
   PubMed Web of Science ®Google Scholar
• Okeson JP: Management of temporomandibular disorders and occlusion. 5th ed. St. Louis: Mosby, 2003.
   Google Scholar
• Laskawi R, Rohrbach S: Oromandibular dystonia. Clinical forms, diagnosis and examples of therapy with botulinum toxin. Laryngorhinootologie 2001; 80(12):708–713.
   Web of Science ®Google Scholar
• Evidente VG: Zolpidem improves dystonia in “Lubag” or X-linked dystonia parkinsonism syndrome. Neurol 2002; 58(4):662–663.
   Web of Science ®Google Scholar
• Moreno-Lopez B, de la Cruz RR, Pastor AM, Delgado-Garcia JM, Alvarez FJ: Effects of botulinum neurotoxin type A on the expression of gephyrin in cat abducens motoneurons. J Comp Neurol 1998; 400(1):1–17.
   Web of Science ®Google Scholar
• Hipola D, Mateo D, Gimenez-Roldan, S: Meige’s syndrome: acute and chronic responses to clonazepam and anticholinergics. Eur Neurol 1984; 23(6):474–478.
   Web of Science ®Google Scholar
• Ruzicka E, Roth J, Jech R, Busek P: Subhypnotic doses of zolpidem oppose dopaminergic-induced dyskinesia in Parkinson’s disease. Mov Disord 2000; 15(4):734–735.
   Web of Science ®Google Scholar
• Langer SZ, Arbilla S, Scatton BV, Niddam R, Dubois A: Receptors involved in the mechanism of action of zolpidem. In: Sauvanet JP, Langer SZ, Morselli PL, eds. Imidazopyridines in sleep disorders: a novel experimental and therapeutic approach. New York: Raven Press, 1988:55–70.
   Google Scholar
• Benavides J, Peny B, Ruano D, Vitorica J, Scatton B: Comparative autoradiographic distribution of central omega (benzodiazepine) modulatory site subtypes with high, intermediate and low affinity for zolpidem and alpidem. Brain Res 1993; 604(1–2):240–250.
   Web of Science ®Google Scholar
• Vitek JL: Pathophysiology of dystonia: a neuronal model. Mov Disord 2002; 17 [Suppl] 3:S49–S62.
   Web of Science ®Google Scholar
• Bressman SB: Dystonia update. Clin Neuropharmacol 2000; 23(5):239–251.
   PubMed Web of Science ®Google Scholar
• Nobrega JN, Richter A, Burnharn WM, Loscher W: Alterations in the brain GABAA/benzodiazepine receptor-chloride ionophore complex in a genetic model of paroxysmal dystonia: a quantitative autoradiographic analysis. Neuroscience 1995; 64(1):229–239.
   Web of Science ®Google Scholar
• Perrault G, Morel E, Sanger DJ, Zivkovic B: The interaction between zolpidem and beta-CMC: a clue to the identification of receptor sites involved in the sedative effect of zolpidem. Eur J Pharmacol 1988; 156(2):189–196.
   Web of Science ®Google Scholar